Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK cells with chemotherapy in pancreatic and cholangiocarcinoma after surgery
NCT06730009Phase 2Recruiting
- Sponsor
- Medigen Biotechnology
- Start
- Oct 2024
- Primary completion
- Jan 2029
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Magicell-NK in pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) (4 arms), sponsored by Medigen Biotechnology. Primary endpoints: Treatment-Emergent Adverse Events at 15 months, Laboratory tests at 15 months and 5 more. Started Oct 2024; status: recruiting.
02
Drugs
Magicell-NK
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06730009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730009.